Causes of death in patients with extranodal cancer of unknown primary: searching for the primary site

被引:0
作者
Matias Riihimäki
Akseli Hemminki
Kristina Sundquist
Kari Hemminki
机构
[1] German Cancer Research Centre (DKFZ),Division of Molecular Genetic Epidemiology
[2] Lund University,Center for Primary Health Care Research
[3] University of Helsinki,Cancer Gene Therapy Group, Transplantation Laboratory & Department of Pathology, Haartman Institute
[4] Stanford University School of Medicine,Stanford Prevention Research Center
来源
BMC Cancer | / 14卷
关键词
Cancer of unknown primary; CUP; Cause of death;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 128 条
[1]  
Pentheroudakis G(2007)Cancer of Unknown Primary Site: Missing Primary or Missing Biology? Oncologist 12 418-425
[2]  
Briasoulis E(2011)Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 22 vi64-vi68
[3]  
Pavlidis N(2012)Cancer of unknown primary site Lancet 379 1428-1435
[4]  
Fizazi K(2011)Familial risks in cancer of unknown primary: tracking the primary sites J Clin Oncol 29 435-440
[5]  
Greco FA(2012)Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries? Ann Oncol 23 2720-2724
[6]  
Pavlidis N(2002)Epidemiology of unknown primary tumours Eur J Cancer 38 1810-1812
[7]  
Pentheroudakis G(2002)Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992 Eur J Cancer 38 409-413
[8]  
Pavlidis N(1999)Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma Clin Cancer Res 5 3403-3410
[9]  
Pentheroudakis G(2012)Survival in cancer of unknown primary site: population-based analysis by site and histology Ann Oncol 23 1854-1863
[10]  
Hemminki K(2008)Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature Cancer Treat Rev 34 693-700